🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are escalating worldwide, with estimates suggesting over 82 million instances each year. Particularly high rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, escalating drug resistance and the extremely scarce treatment choices at this time.”

Health officials are increasingly worried about the rise in drug-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Approval

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This approval represents a huge turning point in the treatment of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Global Access

As per findings detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This establishes an equal footing with the typical regimen, which involves an injection and a pill. The trial included hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors on the front lines have voiced positive views. The availability of a one-pill regimen such as this is described as a "critical tool" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for people and to prevent the spread of untreatable gonorrhoea around the world.